Merit Financial Group’s Lucid Diagnostics LUCD Stock Holding History

Merit Financial Group’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7K	Buy	+10,015	New	+$10.8K	﹤0.01%	2349

Other funds holding LUCD

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Merit Financial Group's LUCD Position: Q2 2026 in Review

Merit Financial Group opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 10,015 shares worth $10.7K. The stake represents ﹤0.01% of the portfolio and ranks #2349 among its holdings.

8 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Merit Financial Group held 10,015 shares of Lucid Diagnostics worth $10.7K as of Q2 2026.
Lucid Diagnostics was a new Merit Financial Group position in Q2 2026.
Lucid Diagnostics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2349 holding.
8 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.